PSMA Theranostics: Current Status and Future Directions.

about

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine

P2860

Q57107703-3133DD0B-B16F-46EB-8456-7349BD16DF1C

P2860

PSMA Theranostics: Current Status and Future Directions.

Item

http://www.wikidata.org/entity/Q55023828

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

PSMA Theranostics: Current Status and Future Directions.

@en

PSMA Theranostics: Current Status and Future Directions.

@nl

type

Item

label

PSMA Theranostics: Current Status and Future Directions.

@en

PSMA Theranostics: Current Status and Future Directions.

@nl

prefLabel

PSMA Theranostics: Current Status and Future Directions.

@en

PSMA Theranostics: Current Status and Future Directions.

@nl

P1476

PSMA Theranostics: Current Status and Future Directions

@en

P2093

Hojjat Ahmadzadehfar

http://www.w3.org/2001/XMLSchema#string

Hossein Jadvar

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.

P304

1536012118776068

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1536012118776068

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kambiz Rahbar

Ali Afshar-Oromieh

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29873291

http://www.w3.org/2001/XMLSchema#string

P921

tumor biomarkers

seminal plasma proteins

Anzim

P932

5992796

http://www.w3.org/2001/XMLSchema#string

PSMA Theranostics: Current Status and Future Directions.

about

P2860

P2860

PSMA Theranostics: Current Status and Future Directions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932